Mixed connective tissue disease Future or Investigational Therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
MCTD involves milder disease activity than systemic sclerosis and systemic lupus erythematosus. However mortality rate have been reported to be high in MCTD and it is known that organ damage increase over time even though disease activity decreases. Organ damage over time in patients with MCTD should be assessed further in future studies.
Future or Investigational Therapies
- MCTD involves milder disease activity than systemic sclerosis and systemic lupus erythematosus. However mortality rate have been reported to be high in MCTD and it is known that organ damage increase over time even though disease activity decreases. Organ damage over time in patients with MCTD should be assessed further in future studies.[1]
References
- ↑ Reiseter S, Gunnarsson R, Corander J, Haydon J, Lund MB, Aaløkken TM, Taraldsrud E, Hetlevik SO, Molberg Ø (December 2017). “Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study”. Arthritis Res. Ther. 19 (1): 284. doi:10.1186/s13075-017-1494-7. PMC 5740892. PMID 29268795.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH